Il 17 apc

Manufactured by R&D Systems

Sourced in United States

IL-17-APC is a fluorescently-labeled antibody that binds to the IL-17 protein. It can be used for the detection and quantification of IL-17 in various research applications.

Automatically generated - may contain errors

Lab products found in correlation

Cd8 apc h7, by BD (6 mentions) Cd56 apc, by BD (6 mentions) Cd19 pe cy7, by BD (5 mentions) Cd45ro apc, by BD (5 mentions) Cd3 bv421, by BD (5 mentions) Cd3 percp, by BD (5 mentions) Cd45 v500, by BD (4 mentions) Cd8 fitc, by BD (4 mentions) Cd25 pe cy7, by BD (4 mentions) Cd4 apc h7, by BD (4 mentions) Cd14 apc h7, by BD (3 mentions) Cd24 pe, by BD (3 mentions) Cd127 bv421, by BD (3 mentions) Cd27 fitc, by BD (3 mentions) Cd38 pe cy5, by BD (3 mentions) Cd197 pe, by BD (3 mentions) Cd14 fitc, by BD (3 mentions) Gm csf pe, by BD (2 mentions) Cd45 v500 tnf alpha percp cy5, by BD (2 mentions) Cd16 pe cy7, by BD (2 mentions)

Spelling variants of this product

IL-17 (154 citations) APC-conjugated IL-17 (2 citations)

6 protocols using il 17 apc

Multicolor Flow Cytometry Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following monoclonal antibodies were used in the study: EZH2-Alexa Fluor 488, CD197-PE (CCR7-PE), CD3-PE, granulocyte/macrophage colony-stimulating factor (GM-CSF)-PE, CD16-PE-Cy5, tumor necrosis factor (TNF)-α-PercP-Cy5.5, CD19-PE-Cy7, CD45RO-APC, CD56-APC, CD8-APC-H7, CD14-APC-H7, CD3-BV421, CD45-V450, CD45-V500 (all from BD Biosciences, San Diego, CA), and IL-17-APC (R&D Systems, Minneapolis, MN).

Malhotra S., Villar L.M., Costa C., Midaglia L., Cubedo M., Medina S., Fissolo N., Río J., Castilló J., Álvarez-Cermeño J.C., Sánchez A., Montalban X, & Comabella M. (2018). Circulating EZH2-positive T cells are decreased in multiple sclerosis patients. Journal of Neuroinflammation, 15, 296.

+ Open protocol

+ Expand

Multicolor Flow Cytometry Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following monoclonal antibodies were used in the study: CD8‐FITC, CD27‐FITC, Interferon (IFN)‐gamma‐FITC, CD24‐PE, CD80‐PE, CD197‐PE (CCR7‐PE), CD3‐PerCP, CD38‐PE‐Cy5.5, CD19‐PE‐Cy7, CD25‐PE‐Cy7, programmed death‐ligand 1 (PD‐L1)‐PE‐Cy7, TNF‐alpha‐PerCP‐Cy5.5, CD45RO‐APC, CD56‐APC, HLA‐DR‐APC, CD4‐APC‐H7, CD8‐APC‐H7, CD14‐APC‐H7, CD3‐BV421, CD69‐BV421, CD127‐BV421, CD45‐V500 (all from BD Biosciences, San Diego, CA); interleukin (IL)‐10‐PE (Biolegend, San Diego, CA), and IL‐17‐APC (R&D Systems, Minneapolis, MN).

Medina S., Sainz de la Maza S., Villarrubia N., Álvarez‐Lafuente R., Costa‐Frossard L., Arroyo R., Monreal E., Tejeda‐Velarde A., Rodríguez‐Martín E., Roldán E., Álvarez‐Cermeño J.C, & Villar L.M. (2019). Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients. Annals of Clinical and Translational Neurology, 6(2), 355-363.

+ Open protocol

+ Expand

Multiparametric Immune Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

CD8-FITC, CD20-FITC, CD24-FITC, interferon-gamma (IFNγ)-FITC, interleukin (IL)-1β-FITC, CD27-PE, IL-10-PE, CD197 (CCR7)-PE, GM-CSF-PE, CD3-PerCP, tumor necrosis factor-alpha (TNFα)-PerCP-Cy5.5, CD19-PE-Cy7, CD25-PE-Cy7, programmed death-ligand 1 (PD-L1)-PE-Cy7, CD45RO-APC, CD56-APC, IL-12-APC, IL-6-APC, CD4-APC-H7, CD8-APC-H7, CD14-APC-H7, CD38-APC-H7, CD3-BV421, CD127-BV421, IL-6-BV421, CD45-V500 (BD Biosciences, San Jose, CA), and IL-17-APC (R&D Systems, Minneapolis, MN).

Fernández-Velasco J.I., Kuhle J., Monreal E., Meca-Lallana V., Meca-Lallana J., Izquierdo G., Gascón-Giménez F., Sainz de la Maza S., Walo-Delgado P.E., Maceski A., Rodríguez-Martín E., Roldán E., Villarrubia N., Saiz A., Blanco Y., Sánchez P., Carreón-Guarnizo E., Aladro Y., Brieva L., Íñiguez C., González-Suárez I., Rodríguez de Antonio L.A., Masjuan J., Costa-Frossard L, & Villar L.M. (2021). Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS. Neurology® Neuroimmunology & Neuroinflammation, 8(2), e940.

+ Open protocol

+ Expand

Multicolor Flow Cytometry Panel

Check if the same lab product or an alternative is used in the 5 most similar protocols

For the study of the cell populations, the following monoclonal antibodies were used: Granulocyte/macrophage-colony stimulating factor (GM-CSF)-PE, CD197-PE (CCR7-PE), CD24-PE, Interferon (IFN)-gamma-FITC, CD14-FITC, CD8-FITC, CD27-FITC, CD8-APC-H7, CD4-APC-H7, CD56-APC, CD45RO-APC, CD3-BV421, CD127-BV421, CD45-V500 TNF-alpha-PerCP-Cy5.5, CD38-PE-Cy5.5, CD19-PE-Cy7, CD25-PE-Cy7, CD3-PerCP, (BD Biosciences, San Diego, CA, USA) and IL-17-APC (R&D Systems, Minneapolis, MN, USA).

Pérez-Pérez S., Domínguez-Mozo M.I., Alonso-Gómez A., Medina S., Villarrubia N., Fernández-Velasco J.I., García-Martínez M.Á., García-Calvo E., Estévez H., Costa-Frossard L., Alvarez-Cermeño J.C., Luque-Garcia J.L., Arroyo R., Villar L.M, & Alvarez-Lafuente R. (2020). Acetate correlates with disability and immune response in multiple sclerosis. PeerJ, 8, e10220.

+ Open protocol

+ Expand

Multiparametric Immune Cell Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

For the study of the cell populations, the following monoclonal antibodies were used: Granulocyte/macrophage-colony stimulating factor (GM-CSF)-PE, CD197-PE (CCR7-PE), CD24-PE, Interferon (IFN)-gamma-FITC, CD14-FITC, CD16-PE-Cy7, CD8-FITC, CD27-FITC, CD8-APC-H7, CD4-APC-H7, CD4-PE-Cy7, CD123-Bv421, CD56-APC, CD56-Bv421, CD45RO-APC, CD45-APC-H7, CD3-BV421, CD127-BV421, CD127-FITC, CD45-V500 TNF-alpha-PerCP-Cy5.5, CD38-PE-Cy5.5, CD19-PE-Cy7, CD19-APC, CD25-PE-Cy7, CD3-PerCP, HLA-DR-PerCP, CD11c-PE (BD Biosciences, San Diego, CA, USA) and IL-17-APC (R&D Systems, Minneapolis, MN, USA).

Dominguez-Mozo M.I., Perez-Perez S., Villarrubia N., Costa-Frossard L., Fernandez-Velasco J.I., Ortega-Madueño I., Garcia-Martinez M.A., Garcia-Calvo E., Estevez H., Luque Garcia J.L., Torrejon M.J., Arroyo R., Villar L.M, & Alvarez-Lafuente R. (2021). Herpesvirus Antibodies, Vitamin D and Short-Chain Fatty Acids: Their Correlation with Cell Subsets in Multiple Sclerosis Patients and Healthy Controls. Cells, 10(1), 119.

+ Open protocol

+ Expand

Multiparameter Flow Cytometry of CSF

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following monoclonal antibodies were used in the study: CD14-FITC, IFN-γ-FITC, GM-CSF-PE, CD3-PerCP, TNF-α-PerCP-Cy5.5, CD16-PE-Cy7, CD19-PE-Cy7, CD56-APC, CD8-APC-H7, CD3-BV421, and CD45-V500 (BD Biosciences, San Diego, CA). IL-17-APC was obtained from R&D Systems, Minneapolis, MN. For patients whose CSF samples were 3-5 ml (36 M+ and 86 M- patients), only a tube measuring surface antigens was studied. In cases of 5-8 ml of CSF (36 M+ and 105 M- patients), the samples were divided into two identical aliquots, and surface antigens and intracellular cytokine production were studied as detailed below. The precise CSF volume used in every case was recorded to calculate total cell numbers.

Picón C., Tejeda-Velarde A., Fernández-Velasco J.I., Comabella M., Álvarez-Lafuente R., Quintana E., Sainz de la Maza S., Monreal E., Villarrubia N., Álvarez-Cermeño J.C., Domínguez-Mozo M.I., Ramió-Torrentà L., Rodríguez-Martín E., Roldán E., Aladro Y., Medina S., Espiño M., Masjuan J., Matute-Blanch C., Muñoz-San Martín M., Espejo C., Guaza C., Muriel A., Costa-Frossard L, & Villar L.M. (2021). Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis. Frontiers in Immunology, 12, 685139.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!